Christopher Clinton Conway: Renewable T Cells via Engineered Stem Cells
Christopher Clinton Conway, Chief Executive Officer & Board Executive Committee at Tower Cancer Research Foundation, shared on LinkedIn:
“UCLA Researchers Supported by Tower Cancer Engineer Stem Cells to Generate Renewable Cancer-Fighting T Cells
In a groundbreaking advance that could redefine the future of cancer immunotherapy, UCLA researchers funded by a major grant from Tower Cancer Research Foundation, have successfully demonstrated the capacity to genetically engineer a patient’s own blood-forming stem cells to produce an enduring supply of functional T cells.
These potent immune cells serve as the body’s primary agents in identifying and eradicating cancer cells. By transforming the patient’s hematopoietic stem cells into a persistent in vivo ‘factory’ for tumor-targeted T cells, this novel approach holds promise for overcoming critical limitations seen in current immunotherapy treatments, particularly against notoriously resistant solid tumors.”
More posts featuring Christopher Clinton Conway.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023